EP1210091A4 - Traitement des aigreurs d'estomac - Google Patents

Traitement des aigreurs d'estomac

Info

Publication number
EP1210091A4
EP1210091A4 EP00947221A EP00947221A EP1210091A4 EP 1210091 A4 EP1210091 A4 EP 1210091A4 EP 00947221 A EP00947221 A EP 00947221A EP 00947221 A EP00947221 A EP 00947221A EP 1210091 A4 EP1210091 A4 EP 1210091A4
Authority
EP
European Patent Office
Prior art keywords
heartburn treatment
heartburn
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00947221A
Other languages
German (de)
English (en)
Other versions
EP1210091A1 (fr
Inventor
Kenneth G Mandel
Steven M Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1210091A1 publication Critical patent/EP1210091A1/fr
Publication of EP1210091A4 publication Critical patent/EP1210091A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00947221A 1999-07-12 2000-07-12 Traitement des aigreurs d'estomac Withdrawn EP1210091A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14340799P 1999-07-12 1999-07-12
US143407P 1999-07-12
PCT/US2000/018896 WO2001003707A1 (fr) 1999-07-12 2000-07-12 Traitement des aigreurs d'estomac

Publications (2)

Publication Number Publication Date
EP1210091A1 EP1210091A1 (fr) 2002-06-05
EP1210091A4 true EP1210091A4 (fr) 2009-07-29

Family

ID=22503933

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00947221A Withdrawn EP1210091A4 (fr) 1999-07-12 2000-07-12 Traitement des aigreurs d'estomac

Country Status (5)

Country Link
EP (1) EP1210091A4 (fr)
JP (2) JP2003504338A (fr)
AU (1) AU6087100A (fr)
CA (1) CA2378018A1 (fr)
WO (1) WO2001003707A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
MXPA03005384A (es) * 2000-12-28 2004-05-05 Tap Pharmaceutical Prod Inc Composiciones framaceuticas de un inhibidor de bomba de proton revestido no enterico con una combinacion de sal de bicarbonato y sal de carbonato.
AU2003900096A0 (en) * 2003-01-10 2003-02-20 Nature Vet Orally deliverable pharmaceutical composition protein pump inhibitors
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2006528182A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 薬学的製剤および酸に起因する消化器疾患の治療法
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP3471725A4 (fr) * 2016-06-16 2020-01-22 Cutispharma, Inc. Composition et procédé de suspension d'inhibiteur de pompe à protons
CA3036356A1 (fr) 2016-09-09 2018-03-15 Cutispharma, Inc. Suspensions et diluants pour le metronidazole et le baclofene
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension
US10751333B1 (en) 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05194225A (ja) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
EP0761212A2 (fr) * 1995-09-08 1997-03-12 Takeda Chemical Industries, Ltd. Composition effervescente et sa préparation
WO1997025066A1 (fr) * 1996-01-08 1997-07-17 Astra Aktiebolag Formes galeniques par voie orale comprenant un inhibiteur de la pompe a protons et un agent antiacide ou un alginate
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
EP1004305A1 (fr) * 1998-04-20 2000-05-31 Eisai Co., Ltd. Compositions stabilisees contenant des composes du type benzimidazole

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3833314B2 (ja) * 1995-09-08 2006-10-11 武田薬品工業株式会社 発泡性組成物およびその製造方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05194225A (ja) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
EP0761212A2 (fr) * 1995-09-08 1997-03-12 Takeda Chemical Industries, Ltd. Composition effervescente et sa préparation
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
WO1997025066A1 (fr) * 1996-01-08 1997-07-17 Astra Aktiebolag Formes galeniques par voie orale comprenant un inhibiteur de la pompe a protons et un agent antiacide ou un alginate
EP1004305A1 (fr) * 1998-04-20 2000-05-31 Eisai Co., Ltd. Compositions stabilisees contenant des composes du type benzimidazole

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
63RD ANNUAL MEETING OF THE AMERICAN COLLEGE OF GASTROENTEROLOGY, October 1998 (1998-10-01), Boston, MA *
ANONYMOUS: "Gastroesophageal Reflux Disease", MERCK MANUAL,, vol. 18th edition, 1 January 2006 (2006-01-01), pages 112 - 113, XP007920470 *
DATABASE WPI DERWENT PUBLICATIONS LTD., LONDON, GB; 1993, "Anti-ulcer agent - contains benzimidazole cpd., amino acid and buffer, giving good stability", XP002280819 *
LIND T ET AL: "Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response.", SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY OCT 1997, vol. 32, no. 10, October 1997 (1997-10-01), pages 974 - 979, XP009118786, ISSN: 0036-5521 *
RICHTER J E ET AL: "Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis", ALIMENTARY PHARMACOLOGY & THERAPEUTICS, BLACKWELL SCIENTIFIC PUBLICATIONS LTD., CAMBRIDGE, GB, vol. 13, no. 6, 1 June 1999 (1999-06-01), pages 795 - 804, XP002463631, ISSN: 0269-2813 *
See also references of WO0103707A1 *
SHARMA V K ET AL: "SIMPLIFIED LANSOPRAZOLE SUSPENSION-A LIQUID FORMULATION OF LANSOPRAZOLE EFFECTIVELY SUPPRESSES INTRAGASTRIC ACIDITY WHEN ADMINISTERED THROUGH A GASTROSTOMY", AMERICAN JOURNAL OF GASTROENTEROLOGY, ELSEVIER SCIENCE INC, US, vol. 94, no. 7, 1 August 1999 (1999-08-01), pages 1813 - 1817, XP002907013, ISSN: 0002-9270 *

Also Published As

Publication number Publication date
JP2003504338A (ja) 2003-02-04
CA2378018A1 (fr) 2001-01-18
WO2001003707A1 (fr) 2001-01-18
JP2012153712A (ja) 2012-08-16
EP1210091A1 (fr) 2002-06-05
AU6087100A (en) 2001-01-30

Similar Documents

Publication Publication Date Title
DE50002490D1 (en) Polyester-polyetherblockcopolymere
DE50002614D1 (en) Sigma-delta-modulator
PL362855A1 (en) Improved treatment
DE50000137D1 (en) Spirofluorenopyrane
GB9925136D0 (en) Novel treatment
EP1210091A4 (fr) Traitement des aigreurs d'estomac
IL144186A0 (en) Novel treatment
DE10081629D2 (en) Seilzugbefestigung
GB9922830D0 (en) Processes
GB9901838D0 (en) Slurry treatment
AU141428S (en) Turnpiece
GB0031321D0 (en) Treatment
GB2356643B (en) Woven-fabric treatment
GB9818524D0 (en) Inorgasmia treatment
GB9815497D0 (en) Treatment
AU140373S (en) Bumbag
GB0206401D0 (en) Side effects treatment
GB9908993D0 (en) Treatment
GB9926206D0 (en) Anti-snoring treatment
GB9828550D0 (en) Treatment
GB9916655D0 (en) Novel treatment
GB9909650D0 (en) Novel treatment
GB9920788D0 (en) Novel treatment
GB9920787D0 (en) Novel treatment
GB9923740D0 (en) Surface treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020122

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20090701

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/48 20060101ALI20090625BHEP

Ipc: A61K 45/06 20060101ALI20090625BHEP

Ipc: A61K 9/28 20060101ALI20090625BHEP

Ipc: A61K 31/4439 20060101ALI20090625BHEP

Ipc: A61K 31/44 20060101AFI20090625BHEP

Ipc: A61P 1/04 20060101ALI20090625BHEP

Ipc: A61K 47/02 20060101ALI20090625BHEP

Ipc: A61K 33/06 20060101ALI20090625BHEP

17Q First examination report despatched

Effective date: 20090908

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GLAXOSMITHKLINE LLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121030